Obesity Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
DelveInsight’s “Obesity Pipeline insight 2023 report“ provides comprehensive global coverage of available, marketed, and pipeline Obesity therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Obesity pipeline domain.
Obesity Overview
Obesity is a chronic and non-communicable disease which involves excess unwanted body fat. Obesity can imbalance the metabolism of the body and is a toll on a person’s psychological health. Obesity diagnoses are not usually by a medical disorder but by lifestyle style. Obesity treatment is losing weight by opting for healthier options and better life choices.
Some of the key takeaways from the Obesity Pipeline Report:
• Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. Obesity Key players such as – D&D Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical,Bukwang Pharmaceutical,Yuhan,Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics,Eli Lilly and Company , and others, are developing therapies for the Obesity treatment
• Obesity Emerging therapies such as – DD03,CBW-520,NPM 139, BK-1701,YH34160, TNX-2900,Thermostem,SCO-267, CT-181, HM15136,NNC0480-0389, XW003,EMP-16,CT-868, and others are expected to have a significant impact on the Obesity market in the coming years.
Discover more about the emerging Obesity drugs @ Obesity Treatment Drug
Emerging Obesity Drugs Under Different Phases of Clinical Development Include:
• DD03- D&D Pharmatech
• CBW-520- Caliway Biopharmaceutics
• NPM 139- Nano Precision Medical
• BK-1701- Bukwang Pharmaceutical
• YH34160- Yuhan
• TNX-2900- Tonix Pharmaceuticals
• Thermostem- BioRestorative Therapies
• SCO-267- SCOHIA PHARMA
• CT-181- Click Therapeutics
• M15136- Hanmi Pharmaceuticals
• NNC0480-0389- Novo Nordisk
• XW003- Sciwind Biosciences
• EMP-16- Empros Pharma
• CT-868- Carmot Therapeutics
• Tirzepatide- Eli Lilly and Company
• Semaglutide Oral- Novo Nordisk
Obesity Pipeline Analysis:
The Obesity pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Obesity treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
• Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Obesity Market Drivers
• Changing lifestyle patterns
• Increase in Obesity diagnosis
• Rise in research and development activities of novel therapies for obesity treatment.
Obesity Market Barriers
• Economic Burden
• Hurdles that come along with the discovery of anti-obesity drugs.
Find out more about the Obesity treatment options in development @ Obesity Clinical Trials
Scope of Obesity Pipeline Drug Insight
• Coverage: Global
• Key Obesity Companies: D&D Pharmatech,Caliway Biopharmaceutics, Nano Precision Medical,Bukwang Pharmaceutical,Yuhan,Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics,Eli Lilly and Company , and others
• Key Obesity Therapies: DD03,CBW-520,NPM 139, BK-1701,YH34160, TNX-2900,Thermostem,SCO-267,CT-181,HM15136,NNC0480-0389,XW003,EMP-16,CT-868, and others
• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Table of Contents
1. Introduction
2. Executive Summary
3. Obesity Overview
4. Obesity Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Obesity Therapeutic Assessment
11. Obesity Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Obesity Unmet Needs
14. Obesity Market Drivers and Obesity Market Barriers
15. Appendix
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Navdha Goel
info@delveinsight.com
+1(919)321-6187
